Abstract: |
Effective tumor immunity requires recognition of tumor cells coupled with the activation of host effector responses. Fc receptor (FcR) γ(-/-) mice, which lack the activating FcγR types I and III, did not demonstrate protective tumor immunity in models of passive and active immunization against a relevant tumor differentiation antigen, the brown locus protein gp75. In wild-type mice, passive immunization with mAb against gp75 or active immunization against gp75 prevented the development of lung metastases. This protective response was completely abolished in FcRγ-deficient mice. Immune responses were intact in γ(-/-) mice because IgG titers against gp75 develop normally in γ(-/-) mice immunized with gp75. However, uncoupling of the FcγR effector pathway from antibody recognition of tumor antigens resulted in a loss of protection against tumor challenge. These data demonstrate an unexpected and critical role for FcRs in mediating tumor cytotoxicity in vivo and suggest that enhancement of FcγR-mediated antibody-dependent cellular cytotoxicity by inflammatory cells is a key step in the development of effective tumor immunotherapeutics. |
Keywords: |
controlled study; nonhuman; proteins; animal cell; mouse; animals; mice; bcg vaccine; melanoma; tumor differentiation; animal experiment; animal model; tumor antigen; mice, inbred c57bl; animalia; monoclonal antibody; lung metastasis; antibodies, monoclonal; antigens, neoplasm; membrane glycoproteins; vaccination; melanoma, experimental; tumor immunity; fc receptor; effector cell; immunity; immunoglobulin g2a; tumor rejection; oxidoreductases; glycoprotein; antibody titer; antibody dependent cellular cytotoxicity; active immunization; idiotypic antibody; freund adjuvant; passive immunization; intraperitoneal drug administration; immunization, passive; receptors, fc; peritoneum macrophage; subcutaneous drug administration; female; priority journal; article
|